Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory CNS Tumors
NCT07698899Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-DTPA-omburtamab in central nervous system tumor, medulloblastoma and Central Nervous System Metastasis (CNSM) (4 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Number of participants with toxicities at 8 weeks and Maximum Tolerated Dose at 8 weeks. Started Jul 2026; status: recruiting.
02
Drugs
177Lu-DTPA-omburtamab
03
Conditions
central nervous system tumormedulloblastomaCentral Nervous System Metastasis (CNSM)
Beyond the preview
Go deeper on NCT07698899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07698899.